News & Views
News & Views
First patient dosed in Phase 1 Trial
Iksuda announces first patient dosed in Phase 1 trial of IKS014
First patient dosed in Phase 1 Trial
Iksuda announces first patient dosed in Phase 1 trial of IKS014
Iksuda deepens clinical pipeline
Iksuda Therapeutics deepens clinical pipeline through licensing agreement for Her2 antibody drug conjugate programme from LegoChem Biosciences
LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates
Expanded agreement grants Iksuda access to Legochem Biosciences’ next generation ADC platform for up to six targets
Iksuda Therapeutics closes $47 million financing round
• Funding to accelerate clinical progression of Iksuda’s pipeline of new generation of antibody drug conjugates, targeting tumours with high unmet need • Investment round led by Korean-based Mirae Asset Capital and Celltrion
Iksuda enters license agreement with University of Goettingen
Iksuda Therapeutics enters license agreement with University of Goettingen to develop a new generation of antibody drug conjugates
Licensing agreement with LegoChem Biosciences
LegoChem Biosciences and Iksuda enter Licensing Agreement for Antibody Drug Conjugate program
LCB and Iksuda Enter into a Multi-Target Research Collaboration
LegoChem Biosciences and Iksuda Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates
Forging stable relationships for Antibody-Drug Conjugates
DCs are a class of biopharmaceuticals that target cancer cells while leaving healthy cells alone.
Iksuda Therapeutics presents first data on lead antibody drug conjugate, demonstrating effective tumour regression
IKS01 shows marked anti-tumour efficacy in pre-clinical models of ovarian and lung cancer
Iksuda Therapeutics and Femtogenix sign license agreement
Agreement gives Iksuda access to Femtogenix’s therapeutic payloads to advance lead ADC for difficult-to-treat solid tumours
Iksuda Therapeutics move into The Biosphere and open a US based office
We’re excited to announce our move into a brand new, purpose built facility, The Biosphere at Newcastle Helix.
Glythera Announces Corporate Name Change and Rebranding to Iksuda Therapeutics
New identity reflects transition in corporate focus, from technology licensing to drug development, for previously untreatable cancers
Glythera appoints Professor Kerry Chester to SAB
Appointment supports the development of the Company’s pipeline
Glythera appoints Chief Scientific Officer and strengthens SAB
Dr Robert Lutz appointed as CSO to support development of next-generation PermaLink® Antibody Drug Conjugates
Positive Outcome of Proof-of-Concept Study with Glythera and Follow on Drug Development Partnership
Successful proof-of-concept study leads to Affimer drug conjugate development partnership
Glythera licenses novel payload class from Cancer Research UK for the development of next-generation antibody drug conjugates
Glythera gains exclusive access to Cancer Research UK’s novel CDK11 inhibitor programme for the development of ADCs conjugated using its highly stable conjugation platform, PermaLink®
Glythera and IONTAS enter into license agreement for the development of multiple antibodies for next-generation Antibody Drug Conjugates
IONTAS will provide Glythera with antibodies from its fully human antibody libraries